Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly
If you experience persistent or severe abdominal pain, you should contact your healthcare provider immediately
62, 63 Therefore, WP may be beneficial in reducing exercise-induced intestinal permeability and the risk of endotoxemia and autoimmune disorders
In the STEP 1 and STEP 2 trials, sex was self-reported
Ask the brand directly to confirm the endorser credential shown on the landing page, if it matters to you
The typical dose varies from person to person, so work with your doctor to find the right amount for you
